Skip to main content
Explore URMC

menu

Gynecologic Cancer (Ovary, Peritoneal): Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Research Question:
Which will work better to treat your low-grade serious ovarian or peritoneal cancer: trametinib OR one of the standard treatments available that your doctor will choose for you (either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin [PLD], or topotecan)?

Basic Study Information

Purpose:
In this study, you will get either the trametinib or one of the standard treatments available. You will not get both at the same time.

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02101788?term=NCT02101788&rank=1
Study Reference #: CGYO-16069

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@urmc.rochester.edu

Additional Study Details

Return to Search